Investors

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta’s research and development is currently focused on four disease targets: Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH) and Respiratory Syncytial Virus (RSV).

Enanta has developed novel protease inhibitors and NS5A inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). Enanta’s protease inhibitors, developed through its collaboration with AbbVie, include paritaprevir, which is contained in AbbVie’s marketed DAA regimens for HCV, and ABT-493, Enanta’s next-generation protease inhibitor which AbbVie is developing in phase 3 studies in combination with ABT-530, AbbVie’s next-generation NS5A inhibitor. Enanta has also discovered a cyclophilin inhibitor, EDP-494, a novel host-targeting mechanism for HCV, which is now in a phase 1 clinical development.

Recent News

More News >>

Upcoming Events
There are currently no events scheduled.

More Events >>

Stock Quote
ENTA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$26.39
Change (%) Stock is Down 0.21 (0.79%)
Volume157,041
Data as of 09/23/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Email Alerts

Sign up to receive email alerts whenever Enanta Pharmaceuticals Inc posts new information to the site.

Just enter your email address and click Submit.
 
Investor Relations Contact
Carol Miceli
Director, Investor Relations
Enanta Pharmaceuticals, Inc.
Phone: 617-607-0710
Email: cmiceli@enanta.com

Media Relations Contact
Kari Watson
MacDougall Biomedical Communications
Phone: 781-235-3060
Email: kwatson@macbiocom.com

 ;